Dr. Furman is Director of the CLL Research Center at Weill Cornell Medical College and a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology. His area of focus is on the development of non-chemotherapeutic approaches to treating CLL, and has played an integral part in the development of ibrutinib and idelalisib.
Please contact the doctor's office to verify that your insurance is accepted.
Aetna [HMO, Medicare, PPO]
Aetna [Weill Cornell Employee Plan]
Affinity [Access (Exchange)]
Emblem Select Care
Empire Blue Cross Blue Shield [Blue Priority, Child Health Plus, EPO, HMO, Mediblue (Senior), Pathway (Exchange), PPO]
Empire Blue Cross Blue Shield [Pathway Enhanced]
Empire Blue Cross Blue Shield HealthPlus
Oxford Health Plans [Freedom, Liberty, Medicare Advantage]
Oxford Health Plans [Metro/Core/Charter (HMO)]
Rockefeller University - CoreSource
UnitedHealthcare [Community Plan, Compass (Exchange), EPO, HMO, Medicare, POS, PPO]
1993 Mount Sinai School of Medicine
Residency: 1996 Hospital of the University of Pennsylvania
Fellowship: 1999 NewYork-Presbyterian Hospital/Weill Cornell Medical Center